Citable filing context

WAT filing events and research context

Server-rendered

WAT's research view summarizes recent SEC filing context, starting with mda_quarterly from May 12, 2026.

WAT filing events and research context
FiledItemContext
May 12, 2026mda_quarterlyWaters Corporation reported a 91% year-over-year revenue increase to $1,267 million for the quarter ended April 4, 2026, primarily driven by the acquisition of Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions (BDS) business. Despite this top-line growth, the company reported an operating loss of $47 million, compared to an operating income of $151 million in the prior-year period. This loss was largely attributable to acquisition-related charges, including $140 million in purchased intangibles amortization, $99 million in inventory and fixed asset fair value step-ups, and $83 million in transaction and integration costs. Excluding the BDS impact, legacy revenue grew 13%, bolstered by demand for liquid chromatography (LC) and mass spectrometry (MS) systems, specifically the Acquity and Xevo TQ-S lines. Geographically, revenue grew significantly in China (68%) and the United States (92%). Total debt reached $5.3 billion following the issuance of $3.5 billion in senior notes to refinance the SpinCo Delayed Draw Term Loan. Key risks include the successful integration of the BDS business, potential supply chain disruptions stemming from evolving tariff policies and recent Supreme Court rulings, and economic volatility in the Chinese market.
Feb 23, 2026businessWaters Corporation specializes in the design, manufacture, and service of analytical instruments and consumables, primarily through its Waters segment, which focuses on liquid chromatography (LC) and mass spectrometry (MS), and its TA segment, which provides thermal analysis, rheometry, and calorimetry instruments. The company serves three primary customer classes: pharmaceutical, industrial, and academic/government, with the pharmaceutical sector acting as the largest revenue driver. Geographically, sales are diversified across the Americas, Europe, and Asia. Strategic growth has been driven by acquisitions, including Wyatt Technology and Halo Labs. In February 2026, Waters completed a transformative $16.8 billion acquisition of BD Biosciences & Diagnostic Solutions via a Reverse Morris Trust, significantly expanding its scale in life sciences and diagnostics. This transaction prompted a corporate reorganization into four new segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. To facilitate this expansion, the company has significantly increased its leverage, assuming $4 billion in unsecured term loans. To mitigate the resulting interest rate volatility associated with this debt, Waters has implemented interest rate swap agreements with an aggregate notional value of $1 billion.
Feb 23, 2026mdaWaters Corporation, a global leader in analytical instruments and software for life, materials, and food sciences, generates 59% of its sales from the pharmaceutical industry and 69% from non-U.S. operations across over 35 countries. Foreign currency fluctuations significantly impact net sales, costs, and balance sheet, a risk managed through natural hedges and short-term foreign currency exchange contracts for major currencies like the Euro, Japanese Yen, British Pound, Mexican Peso, and Brazilian Real. Interest rate risk on variable-rate debt, specifically the Credit Facility, is mitigated by interest rate swaps. The company's net sales increased to $3.165 billion in 2025, with net income remaining stable at $642.6 million. Total debt decreased to $1.407 billion in 2025. Waters recently acquired Halo Labs for $35 million in 2025, building on the $1.3 billion Wyatt acquisition in 2023, which expanded its large molecule application portfolio. A significant post-period event includes the assumption of $4.0 billion in bridge financing for the BD Biosciences & Diagnostic Solutions acquisition, with plans to refinance $3.5 billion. The company experienced a workforce reduction in China in 2024 due to lower demand, incurring $9 million in severance. Sales typically exhibit fourth-quarter seasonality.

Source: SEC EDGAR filing text and events; period May 12, 2026; filed May 12, 2026.

Continue research

Keep researching WAT

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →